Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
Esophageal Cancer - Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer
Exelixis, Inc. - Exelixis and BMS Report Phase 2 Data to Be Presented at ASCO for XL184 in Patients with Previously Treated Glioblastoma Multiforme
Halozyme Therapeutics, Inc. - Phase 1 Study for Halozyme’s Insulin-PH20 Published, Highlights Findings for Faster Acting Insulin Formulations
Hepatitis C Virus - Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
Leukemia - Access Pharmaceuticals Announces Publication of Thiarabine Combination Data
Liver Disease - Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study
Prostate Cancer - PROSTVAC(TM) Data Presented at the ASCO Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late-Stage Prostate Cancer
Schizophrenia - Study Demonstrating Lurasidone Is Effective in Patients With Schizophrenia Published in the Journal of Clinical Psychiatry
Acute Myeloid Leukemia - Reports from Y. Kobayashi et al highlight recent research in acute myeloid leukemia
Emphysema - Research reports from Temple University provide new insights into emphysema
Epilepsy - Findings from S.A. Cross and co-researchers advance knowledge in epilepsy
Graft-Versus-Host Disease - Reports outline graft-versus-host disease research from C. Martinez and colleagues
Human Papillomavirus Vaccines - Findings in human papillomavirus vaccines reported from E. Barthell and co-researchers
Pharmacodynamics - Reports summarize pharmacodynamics research from E. Vets and co-authors
Prostate Cancer - New findings in prostate cancer described by J. Horti and co-researchers
Angiogenesis - Scientists at Nanjing Medical University, Department of Cardiovascular Medicine discuss research in angiogenesis
Colon Cancer Therapy - Study results from Cancer Center update understanding of colon cancer therapy
Abraxis BioScience, Inc. - Study Explores Potential Benefit of Nab®-Paclitaxel in Combination with Bevacizumab for the First-Line Treatment of Metastatic Breast Cancer
Alder Biopharmaceuticals, Inc. - Alder Biopharmaceuticals Presents Results From Phase 1 Trial of ALD518 in Advanced Cancer at American Society of Clinical Oncology Annual Meeting
Amyotrophic Lateral Sclerosis - AIMSPRO is Awarded TGA Orphan Status for the Treatment of Amyotrophic Lateral Sclerosis
Bavarian Nordic A/S - PROSTVAC Data Presented at the ASCO Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late-Stage Prostate Cancer
BioLineRx Ltd. - BioLineRx Announces Positive Preliminary Results From the Phase I/II Trial of BL-1040, the First Injectable Device Addressing Pathological Cardiac Remodeling
Brain Cancer - Neurobiological Technologies' Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
Breast Cancer - CuraGen Updates CR011-vcMMAE Data at ASCO
Breast Cancer - Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting
Can-Fite BioPharma - Can-Fite-Completed Patient Enrollment for the Phase II Trial in Psoriasis With CF101
Cancer - Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
Cancer - Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
Celldex Therapeutics, Inc. - Celldex Therapeutics Announces CDX-1307 Clinical Data at 45th Annual ASCO Meeting
Celldex Therapeutics, Inc. - Pfizer and Celldex Therapeutics Present Update on CDX-110 PF-04948568 Phase 2 Brain Cancer Studies at 45th Annual ASCO Meeting
ChemGenex Pharmaceuticals Limited - Pivotal Study Results: ChemGenex’s Omacetaxine May Provide the First Viable Drug Treatment Option for Patients With a Highly Resistant Form of CML
Chronic Lymphocytic Leukemia - Trubion Announces Positive Data From a Phase 1 / 2 Study of TRU-016 for the Treatment of Chronic Lymphocytic Leukemia (CLL)
Clinical Trial Research - OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
Colon Cancer - AEterna Zentaris Partner Keryx Reports Positive Phase 2 Data for Perifosine (KRX-0401) in Colon and Kidney Cancer at ASCO Meeting
Colon Cancer - Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Adv
Concert Pharmaceuticals - Concert Pharmaceuticals and GlaxoSmithKline Form Alliance to Develop Novel Deuterium Modified Drugs
Crohn Disease - New One-Year Data from REMICADE(R) SONIC Trial Show Sustained Efficacy Compared with Azathioprine in Treatment of Crohn's Disease
Crohn Disease - PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryx's Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
Depomed, Inc. - Depomed Completes Enrollment of Phase 3 Clinical Program of DM-1796 in Post-Herpetic Neuralgia
Drug Development - Cordex Receives Special Protocol Assessment Approval from FDA for ATPace(TM)
Elan Corporation, plc and Biogen Idec - Subset Data from Two Randomized Phase 3 Trials Show TYSABRI® Significantly Improves Health-Related Quality of Life for Crohn’s Disease Patients with Prior Exposure or Inadequate Response to Anti-TNFa Therapy
Enzo Biochem, Inc. - Data from Enzo Therapeutics’ Phase II Study of Crohn’s Disease Presented at Prestigious Gastroenterology Conference
Exelixis, Inc. - Exelixis Reports Encouraging Phase 1 Data To Be Presented at ASCO for XL765, a Dual Inhibitor of PI3K and mTOR
Gene Therapy - PARI Pharma Reports Successful Phase Ib Clinical Results for Inhaled Liposomal Cyclosporine a and Gains FDA Orphan Drug Designation for the Prevention and Treatment of Bronchiolitis Obliterans
Genta Incorporated - New Clinical Data for Tesetaxel, a Leading Oral Taxane, Show Anticancer Activity and Acceptable Safety in Ongoing Study
Genzyme Corp. - Genzyme Completes Transaction with Bayer HealthCare
Gloucester Pharmaceuticals - Gloucester Pharmaceuticals Presents Positive Clinical Data for Romidepsin in CTCL and Further Preclinical Evidence of Synergism with Bortezomib at ASCO
GlycoMimetics, Inc. - Dana-Farber Cancer Institute Presents Results of GlycoMimetics’ Lead Drug Candidate in Models of Multiple Myeloma at American Society of Clinical Oncology Annual Meeting
Head and Neck Cancer - Induction Chemotherapy Followed by ChemoRadiotherapy Increased Time-to-Treatment Failure Compared to ChemoRadiotherapy Alone in Patients With Unresectable Locally Advanced Head & Neck Cancer
Heart Failure - Results and Additional Analyses From Study Show That Corthera's Relaxin for Acute Heart Failure is the Strongest Predictor of Improved Longer-Term Outcomes Following Hospital Discharge When Compared to Other Variables
Horizon Therapeutics, Inc. - Horizon Therapeutics' HZT-501 Significantly Reduces Incidence of NSAID-Induced Upper Gastrointestinal Ulcers in Patients With Mild-to-Moderate Pain
Kureczka/Martin Associates - ChemGenex's omacetaxine may provide first viable treatment option for highly resistant form of CML
Merck & Co., Inc. and AstraZeneca - AstraZeneca and Merck & Co., Inc. Form Pioneering Collaboration to Investigate Novel Combination Anticancer Regimen
Merck KGaA - Merck KGaA: Follow-Up From Stimuvax Study Provides Long-Term Safety Data In Advanced Lung Cancer Patients Receiving Treatment for Up To 8.2 Years
Merck KGaA - Merck KGaA: Study Shows Cilengitide Increased Overall Survival in Patients With Glioblastoma
Mersana Therapeutics, Inc. - Mersana Reports Preliminary Phase 1 Results of XMT-1001 in Patients with Advanced Solid Tumors
Non-Small Cell Lung Cancer - Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non-Small Cell Lung Cancer
Ovarian Cancer - Telik Presents Results at ASCO From ASSIST-5 Trial of TELCYTA in Platinum Refractory and Resistant Ovarian Cancer
Pfizer - New Pfizer Data Helps to Identify Kidney Cancer Patients Who May Be Most Likely to Benefit from Treatment
Pfizer Inc - Pfizer Data Identify Certain Lung Cancer Patients Who May Benefit from Treatment with Figitumumab
Pfizer Inc - Pfizer Discontinues SUN 1094 Trial of Sunitinib plus Paclitaxel in Advanced Breast Cancer
Pfizer Inc - Pfizer Presents Data With Novel Investigational Agents In Select Patient Groups With Non-Small Cell Lung Cancer
Pharmaceuticals - Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
Plexxikon Inc. - Plexxikon Announces PLX4032 Phase 1 Data Showing Objective Responses in Metastatic Melanoma Patients
Prostate Cancer - Isis Highlights New Clinical Data on Anti-Cancer Antisense Drugs Featured at ASCO
Prostate Cancer - Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients
Salix Pharmaceuticals - Salix’s Once-Daily APRISO Demonstrates Long-Term Safety in Patients for Maintenance of Remission from Ulcerative Colitis
Sarah Cannon Research Institute - Sarah Cannon Research Institute to Present Latest Cancer Research Data at National Clinical Oncology Conference
Sarcoma - Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting
Seattle Genetics, Inc. - Seattle Genetics Reports Data from a Weekly Dosing Phase I Clinical Trial of SGN-35 in Lymphoma
Solid Cancer - LNA-Based HIF-1 Alpha Inhibitor Shows Early Signs of Clinical Benefit
Solid Cancer - Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting
Solid Cancer - Semafore's SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients
StemCells, Inc. - StemCells, Inc. to Present Phase I Clinical Trial Results at the 12th International Congress on NCL
Tuberculosis - Data On Investigational Drug TMC207 for Treatment of MDR-Tuberculosis, Published in New England Journal of Medicine
Xencor, Inc. - Xencor Presents Preliminary Phase I Data on XmAb®2513 Antibody for Lymphomas at 2009 American Society of Clinical Oncology Annual Meeting
XenoPort, Inc. - XenoPort Data Presented at Digestive Disease Week Meeting Demonstrates Arbaclofen Placarbil Monotherapy Reduces Heartburn and Regurgitation in GERD Patients Previously Treated with PPIs
ZIOPHARM Oncology, Inc. - ZIOPHARM Presents Positive Darinaparsin Clinical Data at ASCO’s Prestigious Clinical Science Symposium
ZIOPHARM Oncology, Inc. - ZIOPHARM Presents Positive Data from Phase I Study of Palifosfamide in Combination with Doxorubicin at ASCO
ZIOPHARM Oncology, Inc. - ZIOPHARM Presents Positive Indibulin Translational and Dose Scheduling Data at ASCO
ZymoGenetics, Inc. - ZymoGenetics Reports Encouraging Phase 2 Results in Renal Cell Cancer for IL-21 with Nexavar®
